Clinical Trials Logo

NHL clinical trials

View clinical trials related to NHL.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05365100 Withdrawn - NHL Clinical Trials

A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

Start date: July 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN102 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin's Lymphoma (NHL)

NCT ID: NCT05176691 Withdrawn - Follicular Lymphoma Clinical Trials

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Start date: February 15, 2022
Phase: Phase 1
Study type: Interventional

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL

NCT ID: NCT02847949 Withdrawn - NHL Clinical Trials

A Study of IGN002 for Refractory NHL

Start date: January 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1 multi-center, open-label study that allows subjects who derived clinical benefit after completing IGN002 treatment in the Spectrum sponsored IGN002-101 study to continue treatment with IGN002. Subjects who completed the IGN002-101 study, tolerated IGN002 treatment, and did not experience progressive disease (PD) are eligible to participate in this study.

NCT ID: NCT01101581 Withdrawn - Clinical trials for Diffuse Large B-cell Lymphoma

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Start date: May 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to evaluate a new approach to immunotherapy in NHL by combining two antibodies, veltuzumab and epratuzumab. For treatment, epratuzumab has also been attached to a radioactive isotope called 90yttrium (90Y-epratuzumab). Veltuzumab and 90Y-epratuzumab attack different areas on lymphoma cells. Because of this, treatment with the combination may provide more effective treatment in NHL than either veltuzumab or 90Y-epratuzumab given alone.